When does rucaparib’s patent expire?
Rucaparib (Rubraca) has had different patents covering specific elements such as the molecule itself, formulations, and method-of-use claims. Because patent expiry depends on the country and on the specific patent/patent family (and whether extensions apply), there is not one single global “patent expiry date” for rucaparib. The only way to get an exact date is to identify the relevant patent(s) for the jurisdiction you care about.
How to find the exact rucaparib patent expiry date (by country)
To determine the exact expiry date for rucaparib in a given market, you typically need:
- The country (e.g., US, UK, EU member state, or a specific national jurisdiction).
- The specific product/claim being protected (drug substance vs. formulation vs. dosing regimen).
- The underlying patent number(s) and any patent term adjustments or extensions.
This information is then checked in that jurisdiction’s patent registers (and sometimes linkage resources that show which patents are tied to marketing authorization).
What about “exclusivity” vs “patent expiry” for rucaparib?
Even after a patent expires, additional market protections can delay generic or biosimilar entry, depending on local rules. These can include:
- Supplementary protection certificates (SPCs) in parts of Europe
- Data exclusivity or marketing exclusivity periods
- Patent-prosecution-related extensions (where applicable)
So the date the first relevant patent expires may not match the first date generics can launch.
If you tell me the country, I can narrow to the right expiry date
If you share:
1) the country (or EMA/UK/US, etc.), and
2) whether you mean “first generic launch date” or the “expiry of the core drug patent,”
I can point you to the specific patent(s) to check and the likely expiry/earliest launch timing for rucaparib in that jurisdiction.